MYCN and neuroblastoma: Strengthening diagnostic and therapeutic capabilities in middle-SDI regions is paramount, alongside investments in genetic and molecular research, such as exploring the role of MYCN amplification in neuroblastoma, to support the development of personalized treatment approaches.